{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T14:18:38Z","timestamp":1782310718427,"version":"3.54.5"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1053\/j.seminhematol.2005.11.006","type":"journal-article","created":{"date-parts":[[2006,1,20]],"date-time":"2006-01-20T07:44:19Z","timestamp":1137743059000},"page":"S108-S110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"S1","title":["High-Dose Recombinant Factor VIIa Therapy in Hemophilia Patients With Inhibitors"],"prefix":"10.1053","volume":"43","author":[{"given":"Gili","family":"Kenet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2005.11.006_bib1","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1365-2141.2005.05605.x","article-title":"Environmental risk factors for inhibitor development in children with haemophilia A","volume":"130","author":"Santagostino","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2005.11.006_bib2","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1111\/j.1538-7836.2005.01375.x","article-title":"Cellular immune responses in hemophilia","volume":"3","author":"White","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1053\/j.seminhematol.2005.11.006_bib3","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1055\/s-2000-9821","article-title":"Inhibitor antibodies to factor VIII and factor IX","volume":"26","author":"Lusher","year":"2000","journal-title":"Semin Thromb Hemost"},{"key":"10.1053\/j.seminhematol.2005.11.006_bib4","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1055\/s-2000-8457","article-title":"Pharmacokinetics of recombinant activated factor VII (rFVIIa)","volume":"26","author":"Erhardtsen","year":"2000","journal-title":"Semin Thromb Hemost"},{"key":"10.1053\/j.seminhematol.2005.11.006_bib5","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1055\/s-0037-1615357","article-title":"Prospective, randomized trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery","volume":"80","author":"Shapiro","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.seminhematol.2005.11.006_bib6","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1055\/s-0037-1615388","article-title":"Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors","volume":"80","author":"Key","year":"1998","journal-title":"Thromb Haemost"},{"issue":"suppl 1","key":"10.1053\/j.seminhematol.2005.11.006_bib7","first-page":"S107","article-title":"Home treatment with recombinant activated factor VII","volume":"9","author":"Ingerslev","year":"1998","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1053\/j.seminhematol.2005.11.006_bib8","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1160\/TH03-05-0301","article-title":"Injection of recombinant activated factor VII can induce transient increase in circulating procoagulant microparticles","volume":"91","author":"Proulle","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.seminhematol.2005.11.006_bib9","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1055\/s-0037-1613465","article-title":"Effects of recombinant factor VIIa on platelet function and clot structure in blood with deficient prothrombin conversion","volume":"89","author":"Carr","year":"2003","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.seminhematol.2005.11.006_bib10","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1538-7836.2005.01127.x","article-title":"The effect of platelets on fibrin gel structure formed in the presence of recombinant factor VIIa in hemophilia plasma and in plasma from a patient with Glanzmann thrombasthenia","volume":"3","author":"He","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1053\/j.seminhematol.2005.11.006_bib11","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/00001721-199811000-00003","article-title":"The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0","volume":"9","author":"Erhardtsen","year":"1998","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1053\/j.seminhematol.2005.11.006_bib12","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/0049-3848(96)00028-X","article-title":"Variability in platelet procoagulant activity in healthy volunteers","volume":"81","author":"Sumner","year":"1996","journal-title":"Thromb Res"},{"key":"10.1053\/j.seminhematol.2005.11.006_bib13","first-page":"S97","article-title":"Experiences with continuous infusion of recombinant activated factor VII","volume":"9","author":"Schulman","year":"1998","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1053\/j.seminhematol.2005.11.006_bib14","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2516.2004.00925.x","article-title":"Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A","volume":"10","author":"Villar","year":"2004","journal-title":"Haemophilia"},{"key":"10.1053\/j.seminhematol.2005.11.006_bib15","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/j.1538-7836.2004.00759.x","article-title":"Recombinant factor VIIa","volume":"2","author":"Abshire","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1053\/j.seminhematol.2005.11.006_bib16","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1046\/j.1538-7836.2003.00059.x","article-title":"A new approach to treatment of bleeding episodes in young hemophilia patients","volume":"1","author":"Kenet","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1053\/j.seminhematol.2005.11.006_bib17","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1046\/j.1365-2516.2001.00553.x","article-title":"Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures","volume":"7","author":"Cooper","year":"2001","journal-title":"Haemophilia"},{"key":"10.1053\/j.seminhematol.2005.11.006_bib18","first-page":"53","article-title":"High dose recombinant activated factor VII for treatment of patients with hemophilia and inhibitors","volume":"10","author":"Kenet","year":"2004","journal-title":"Haemophilia"},{"key":"10.1053\/j.seminhematol.2005.11.006_bib19","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1365-2516.2005.01075.x","article-title":"Dose effect and efficacy of recombinant factor VIIa (rFVIIa) in the treatment of haemophilia patients with inhibitors","volume":"11","author":"Parameswaran","year":"2005","journal-title":"Haemophilia"},{"key":"10.1053\/j.seminhematol.2005.11.006_bib20","series-title":"rFVIIa (NovoSeven) for the treatment of mild\/moderate joint bleeds in haemophilia patients with inhibitors","author":"Kavakli","year":"2005"},{"key":"10.1053\/j.seminhematol.2005.11.006_bib21","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1365-2516.2004.00924.x","article-title":"Unresponsiveness to factor VIII inhibitor bypassing agents during haemostatic treatment for life-threatening massive bleeding in a patient with haemophilia A and a high responding inhibitor","volume":"10","author":"Hayashi","year":"2004","journal-title":"Haemophilia"},{"key":"10.1053\/j.seminhematol.2005.11.006_bib22","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1365-2516.2004.00912.x","article-title":"Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors","volume":"10","author":"Schneiderman","year":"2004","journal-title":"Haemophilia"},{"key":"10.1053\/j.seminhematol.2005.11.006_bib23","series-title":"Concomitant infusion of low doses of rFVIIa and FEIBA in severe hemophilia A patients with an inhibitor to factor VIII who are refractory to rFVIIa or FEIBA has an excellent hemostatic effect and synergistically enhances thrombin generation.","author":"Martinowitz","year":"2005"},{"key":"10.1053\/j.seminhematol.2005.11.006_bib24","first-page":"539","article-title":"Evolving techniques for monitoring clotting in plasma and whole blood samples","volume":"50","author":"Carr","year":"2004","journal-title":"Clin Lab"},{"key":"10.1053\/j.seminhematol.2005.11.006_bib25","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1365-2516.2005.01141.x","article-title":"Major surgery in a severe haemophilia A patient with high titre inhibitor","volume":"11","author":"Dargaud","year":"2005","journal-title":"Haemophilia"},{"issue":"suppl 1","key":"10.1053\/j.seminhematol.2005.11.006_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2516.2005.01156.x","article-title":"Tailoring haemostatic treatment to patient requirements\u2014An update on monitoring haemostatic response using thrombelastography","volume":"11","author":"Sorensen","year":"2005","journal-title":"Haemophilia"},{"issue":"suppl 1","key":"10.1053\/j.seminhematol.2005.11.006_bib27","first-page":"139","article-title":"Thrombelastgram as a hemostatic monitor during recombinant factor VIIa treatment in hemophilia A patients with inhibitor to factor VIII","volume":"26","author":"Yoshioka","year":"1996","journal-title":"Haemostasis"},{"key":"10.1053\/j.seminhematol.2005.11.006_bib28","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1538-7836.2004.00528.x","article-title":"Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa","volume":"2","author":"Sorensen","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"suppl 1","key":"10.1053\/j.seminhematol.2005.11.006_bib29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/j.seminhematol.2003.11.002","article-title":"Dose optimization of recombinant factor VIIa for control of mild to moderate bleeds in inhibitor patients","volume":"41","author":"Abshire","year":"2004","journal-title":"Semin Hematol"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196305002131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196305002131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:17:11Z","timestamp":1758521831000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196305002131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":29,"alternative-id":["S0037196305002131"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2005.11.006","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2006,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-Dose Recombinant Factor VIIa Therapy in Hemophilia Patients With Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2005.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}